Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics (GALT) reported an insider transaction by its President and CEO, who is also a Director. On 11/05/2025, the executive exercised 200 stock options at $2.39 and sold 200 common shares at $6.00, executed under a Rule 10b5-1 plan.
Following these transactions, the executive reported 832,592 common shares held directly. An additional 2,000 shares are held indirectly as custodian for a minor child under the Uniform Transfers to Minors Act, with beneficial ownership disclaimed. The exercised options were from a grant that vested 100% on 12/14/2018 and expire on 12/14/2027, with 24,230 derivative securities reported as beneficially owned after the transaction.
Galectin Therapeutics (GALT) Form 4: CFO Jack W. Callicutt exercised stock options for 600 shares and sold 600 shares on 11/05/2025 under a Rule 10b5-1 plan. Exercises occurred at $1.98, $1.11, and $1.72 per share, with sales at $6. Following these transactions, he held 7,614 shares directly.
Galectin Therapeutics (GALT) reported insider transactions by its President and CEO, who is also a Director. On 11/03/2025 and 11/04/2025, the officer exercised stock options at $2.39 per share for 1,300 and 14,420 shares, respectively, and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on April 17, 2025. Sales were executed at weighted average prices of $6.01 (range: $6.00–$6.01) and $6.07 (range: $6.00–$6.20). Following these transactions, the officer directly beneficially owned 832,592 common shares and held 2,000 shares indirectly as custodian for a minor child under the UTMA. The reported options vested on December 14, 2018 and expire on December 14, 2027.
Galectin Therapeutics (GALT) reported insider transactions by CFO Jack W. Callicutt. On November 3–4, 2025, he exercised employee stock options at $1.11, $1.72, and $1.98 per share and sold the resulting shares under a pre‑arranged Rule 10b5‑1 plan.
Sales on November 3 were executed at a weighted average price of $6.01 (transactions ranged from $6.00–$6.01). On November 4, sales were executed at a weighted average price of $6.07 (range $6.00–$6.25). Individual lots included 1,300, 1,260, and 1,250 shares on November 3, and 8,914, 8,974, and 10,741 shares on November 4.
Following these transactions, the CFO beneficially owned 7,614 shares directly. The options referenced were from grants with previously disclosed vesting schedules.
Galectin Therapeutics (GALT) reported insider transactions by 10X Fund, L.P., 10X Capital Management, LLC, and Director James C. Czirr on 10/22/2025. The filing lists two open‑market sales: 20,000 shares at $4.93 and 30,000 shares at $4.94.
Following these sales, the reporting persons show 5,872,207 shares beneficially owned. The form indicates direct ownership for the reported balance and includes standard footnotes stating that certain parties may be deemed to have indirect beneficial ownership, with ownership disclaimed except to the extent of pecuniary interest.
Galectin Therapeutics (GALT) filed its definitive proxy for the 2025 annual meeting, which will be held virtually on December 3, 2025 at 11:00 a.m. EST via www.virtualshareholdermeeting.com/GALT2025. Holders of Common Stock or Series A 12% Convertible Preferred Stock of record as of October 7, 2025 may vote.
Stockholders will vote on: (1) electing 11 directors, (2) a non-binding “say‑on‑pay” advisory resolution, (3) a non-binding vote on the frequency of say‑on‑pay, and (4) ratification of Cherry Bekaert LLP as independent auditor for fiscal 2025. The Board recommends FOR all proposals and recommends say‑on‑pay votes occur every three years.
Directors and executive officers control voting for approximately 19% of outstanding voting shares and expect to vote FOR all items. Shares outstanding for quorum purposes were 64,479,210 as of the record date. The proxy also details related‑party financing with Richard E. Uihlein, including prior convertible notes (conversion prices $5.00, $8.64, and $5.43), lines of credit up to $60.0 million plus supplemental facilities of $10.0 million, $6.0 million, and $10.0 million (July 2025), warrant issuances tied to draws, and extended maturities to September 30, 2026.
Galectin Therapeutics (GALT) filed a Form 5 reporting insider ownership changes for the year ended 12/31/2024. The filing shows indirect transactions by 10X Fund, L.P. on two dates: a sale of 21,323 shares on 04/22/2024 at $3.06 per share, and a sale of 3,677 shares on 04/23/2024 at $3.06 per share.
The reporting person is marked as a Director, with holdings reported as indirect through 10X Fund, L.P. The disclosure notes that 10X Capital Management, LLC is the general partner of 10X Fund, L.P. and may be deemed to have indirect beneficial ownership, while disclaiming beneficial ownership except to the extent of pecuniary interest.
Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions on Form 4 showing the exercise and sale of common stock on 09/12/2025. The filing discloses the exercise of 8,706 stock options with an exercise price of $1.37 (options originally granted 01/20/2019 and expiring 01/20/2026). Those 8,706 shares were sold the same day under a Rule 10b5-1 plan adopted April 17, 2025, at a weighted average price of $6.4385 (sales ranged $6.33–$6.68). After these transactions the reporting person beneficially owned 7,614 shares, down from 16,320 prior to the transactions. The filing includes an undertaking to provide per-trade sale details on request.
Joel Lewis, President and CEO of Galectin Therapeutics (GALT), reported option exercise and share sale transactions on 09/12/2025. He exercised a stock option with a $2.39 exercise price to acquire 14,000 shares and contemporaneously sold 14,000 shares at a weighted average price of $6.3606, resulting in reported beneficial ownership of 846,592 shares after the acquisition and 832,592 shares after the sale. The option exercised was part of a grant exercisable since 12/14/2018 and expiring 12/14/2027. The filing notes these transactions were made pursuant to a Rule 10b5-1 trading plan adopted April 17, 2025. Mr. Lewis also reports 2,000 shares held indirectly as custodian for a minor, which he disclaims as beneficially owned.